The PennZone

  • Home
  • Entertainment
  • Non-profit
  • Business
  • Education
  • Technology
  • Marketing
  • Music
  • Health

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Scott G. Hoy of Hoy Law Earns 11th Consecutive Super Lawyers Selection
  • Brother Marcus Unlocks the Vault
  • L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • New ProEssentials v11: Native WinUI Charting Library, 100M Points in 15ms, Following Microsoft's Vision for True Native Swap-Chain Rendering
  • New AI Customer Segmentation Guide Warns Marketers Not to Confuse Technical Precision With Business Value
  • Salestrics Releases Version 2.0 to Unify CRM, Business Email, and Operations on a Single Customer Graph
  • Aderra Opens in Magnolia, Texas, Offering a New Model for 62+ Homeownership
  • What's New in Hokkaido, Autumn 2026
  • CRG Awarded NASA SEWP VI Contracts in Categories B and C
  • Heidi G. Villari of The Villari Firm, PLLC Named to Super Lawyers for the Tenth Consecutive Year
  • Elevate Your Sneakers With Crep Protect Trek Laces
  • Meet Privateer: Tucson's High-Tech Security Force Built With Paramilitary Precision
  • Dynamic Dachshund Dog Goes Global: Remember Point Launches a New Bilingual Children's Book
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • From the Racetrack to the Boardroom: Aston Martin and Aramco Formula One Partnership Accelerates Circle8 Group: (N A S D A Q: CIRC)
  • SKRAP Finds Hope Through Heartache on Powerful New Single "Shellshock"
  • CodesClue: A Trusted AI-Based Software Development Company for Global Businesses
  • U.N. Committee Reiterates Forced Psychiatric Detention a Human Rights Violation; CCHR Calls on the U.S. to Implement Protections
  • Valgar LLC Launches The Briefing Room: Education Leaders
  • New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
  • New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000
  • Easwe D10, C20, and C30: Lightweight Folding Electric Wheelchairs Built for Easier Travel
  • Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine

Popular on PennZone

  • Proper Sky Named to the 2026 MSP 501
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Dentists launch independent platform to help practices choose the right technology
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area

Similar on PennZone

  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us